YD Bio Ltd Annual Report: A Plain-English Guide

I’ve put together this guide to help you make sense of YD Bio Ltd’s latest annual report. My goal is to cut through the corporate jargon so you can decide if this company belongs in your portfolio.

1. The Big Picture

YD Bio Ltd is a Taipei-based biotech company listed on the Nasdaq (YDES). They focus on two areas: cancer detection and eye care. The company is currently working to merge with its partner, EG BioMed, to bring more technology and control in-house.

2. The Numbers: Who is paying the bills?

The company relies on a very small group of customers. In 2025, over 53% of their total revenue came from just three clients: Novartis, Zuelling, and Alcon. While these partnerships show industry support, they represent a significant concentration risk. Currently, the company does not earn enough to cover its daily operating costs and relies on outside funding to maintain operations.

3. Financial Health: A Red Flag

The company has explicitly warned there is "substantial doubt" about its ability to stay in business. They are spending cash faster than they generate it, and they have no guaranteed plan to secure additional funding.

Furthermore, they rely heavily on one supplier, 3D Global. In 2025, this partner provided 83.7% of all their materials. Any disruption to this relationship would cause production and clinical trials to grind to a halt.

4. The Strategy: What are they selling?

YD Bio is betting on two pipelines:

• Cancer Detection: They use blood tests to find early-stage cancer. They face intense competition from established industry leaders like Exact Sciences and GRAIL, who possess significantly more data and larger market shares.
• Eye Care: They supply materials for other companies’ clinical trials and are developing their own eye drops and lenses. These products are in the early stages, and the company does not expect to finish trials for its main eye injection until 2032.

5. The Risks

• Conflict of Interest: YD Bio pays royalties to EG BioMed and 3D Global. Both companies are partially owned by YD Bio’s CEO, Dr. Ethan Shen, meaning company spending directly benefits the CEO’s private interests.
• Patent Uncertainty: YD Bio does not own its core technology; it only licenses it. If these licenses are challenged or expire, the company loses the legal right to use the technology behind its products.
• Dilution: The company has over 15 million warrants outstanding at $11.50 each. If these are exercised, the company will issue millions of new shares, which reduces your ownership percentage and could put downward pressure on the stock price.

Bottom Line: This is a high-risk, speculative investment. The company is burning cash, relies on a tiny group of customers, and is heavily tied to the CEO’s other businesses. Its survival depends on securing new funding and navigating a long, expensive road to completing its clinical trials. Before investing, consider whether you are comfortable with the company's current lack of profitability and the significant influence of the CEO's private business interests.